AddLife AB (publ) (ALIF_B) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning everyone, and welcome to the AdLive fourth quarter presentation. This morning we will take you through the highlights of the quarter, and then of course open up for a Q&A session. After that Q&A, we do encourage you to stay on because we have recorded a wonderful video of one of our companies, this time Biolin, a manufacturer of advanced research instruments. So now, let's go. I'm very pleased to note that the AdLab companies were able to wrap up 2025 in a good way. We saw continued profit improvement, we saw strong profit and strong cash flow. On the EBITDA margin account, we saw that Labtech were able to protect the very high level at 14.1% EBITDA margin, same as we had in the strong fourth quarter of last year. And on the Medtech side, it improved to 12% compared to 11.6%. in the corresponding quarter of last year. Overall, we saw healthy customer demand in our markets, but of course currency effects impacted our sales growth, but the currency adjusted sales increased by 2% in the quarter. We are working diligently with profit improvement initiatives, and this is one of the core parts of our business model. We have seen for many quarters now a continuous improvement, and we do expect that to continue in the future as well. In the UK, we have had a long-standing dialogue with a key partner in the area of endoscopy. They have chosen to go direct, and we have supported them in that, handing over the team and the resources related to that business, and we have received the consideration of 158 million kronas in the quarter. So this, in combination with the strong cash flow that we saw, has helped us to achieve a net debt to EBITDA of 2.2. So with this, we achieve our goal of remaining at 3 or below, and we have actually far exceeded the ambition as well. ...